The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.
The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.
CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.
EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.
The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.
The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.
ADA 2019 The REWIND trial, which included a majority of participants without established CVD, showed that dulaglutide treatment resulted in 12% reduction in MACE, irrespective of history of CVD.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.
Comprehensive joint and stratified analyses on sitting, physical activity and all-cause or CV mortality risk evaluated the effects of replacing sitting with various physical activity patterns on mortality risk. With poll.
Bleeding on probing, increased probing pocket depth, caries or fillings in childhood were associated with increased IMT 27 years later, independent of cumulative exposure to CV risk factors.
In a study that aimed to address the healthy donor effect, women who had frequently donated blood in the first 10 years of their donation career, showed fewer CV events than those less often donating.